[go: up one dir, main page]

AR083445A1 - siARN CONTRA LA FIBROSIS - Google Patents

siARN CONTRA LA FIBROSIS

Info

Publication number
AR083445A1
AR083445A1 ARP110103808A ARP110103808A AR083445A1 AR 083445 A1 AR083445 A1 AR 083445A1 AR P110103808 A ARP110103808 A AR P110103808A AR P110103808 A ARP110103808 A AR P110103808A AR 083445 A1 AR083445 A1 AR 083445A1
Authority
AR
Argentina
Prior art keywords
bases
positions
sirna
sirna against
fibrosis
Prior art date
Application number
ARP110103808A
Other languages
English (en)
Original Assignee
Univ Mie
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mie, Otsuka Pharma Co Ltd filed Critical Univ Mie
Publication of AR083445A1 publication Critical patent/AR083445A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

siARN eficaz para el tratamiento de la fibrosis y un producto farmacéutico, que contiene siARN. Un siARN que tiene una longitud completa de 30 o menos nucleótidos y que se dirige a una secuencia que consiste de 17 a 23 bases consecutivas seleccionadas del grupo que consiste en bases en las posiciones 1285 a 1318, bases en las posiciones 1398 a 1418, bases en las posiciones 1434 a 1463, bases en las posiciones 1548 a 1579, bases en las posiciones 1608 a 1628, bases en las posiciones 1700 a 1726, bases en las posiciones 1778 a 1798, bases en las posiciones 1806 a 1826 y bases en las posiciones 1887 a 1907 de SEQ ID Nº 1. El ARN pequeño de interferencia inhibe la expresión del gen TGF-b1. Uso del siARN. Método de tratamiento.
ARP110103808A 2010-10-14 2011-10-13 siARN CONTRA LA FIBROSIS AR083445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010231946 2010-10-14

Publications (1)

Publication Number Publication Date
AR083445A1 true AR083445A1 (es) 2013-02-27

Family

ID=45938402

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103808A AR083445A1 (es) 2010-10-14 2011-10-13 siARN CONTRA LA FIBROSIS

Country Status (30)

Country Link
US (6) US8772262B2 (es)
EP (2) EP3517614A1 (es)
JP (4) JP6022940B2 (es)
KR (2) KR102167225B1 (es)
CN (2) CN103119166B (es)
AR (1) AR083445A1 (es)
AU (1) AU2011314653B2 (es)
BR (1) BR112013006541A2 (es)
CA (1) CA2813163C (es)
CO (1) CO6660456A2 (es)
CY (1) CY1121945T1 (es)
DK (1) DK2628798T3 (es)
ES (1) ES2720135T3 (es)
HR (1) HRP20190722T1 (es)
HU (1) HUE043891T2 (es)
IL (2) IL224791A (es)
LT (1) LT2628798T (es)
MX (1) MX348555B (es)
MY (1) MY165964A (es)
NZ (2) NZ609440A (es)
PH (1) PH12013500361A1 (es)
PL (1) PL2628798T3 (es)
PT (1) PT2628798T (es)
RU (1) RU2583290C2 (es)
SG (3) SG10201508365RA (es)
SI (1) SI2628798T1 (es)
TR (1) TR201905060T4 (es)
TW (2) TWI679023B (es)
WO (1) WO2012050181A1 (es)
ZA (1) ZA201301279B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083445A1 (es) * 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
WO2015093495A1 (ja) * 2013-12-16 2015-06-25 株式会社ボナック ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子
HK1244035A1 (en) 2014-12-15 2018-07-27 Bonac Corporation Single-stranded nucleic acid molecule for inhibiting tgf- beta 1 expression
WO2017043490A1 (ja) * 2015-09-07 2017-03-16 協和発酵バイオ株式会社 自然免疫誘導効果が増強した二重鎖リボ核酸
US10751426B2 (en) * 2015-10-30 2020-08-25 Bonac Corporation Composition stably containing single-stranded nucleic acid molecule that suppresses expression of TGF-β1 gene
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2003035869A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
JP2005512976A (ja) 2001-10-26 2005-05-12 リボファーマ アーゲー Ｒｎａ干渉により線維化疾患を処置するための医薬
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
CN1608133A (zh) 2001-10-26 2005-04-20 里伯药品公司 双链核糖核酸用于治疗正(+)链rna病毒感染的用途
US20040121348A1 (en) 2001-10-26 2004-06-24 Ribopharma Ag Compositions and methods for treating pancreatic cancer
ATE536408T1 (de) * 2003-04-02 2011-12-15 Dharmacon Inc Modifizierte polynukleotide zur verwendung bei rna-interferenz
US7668257B2 (en) * 2003-10-01 2010-02-23 Samsung Electronics Co., Ltd. Transmissions with reduced code rate in 8VSB digital television
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
JP2007119396A (ja) 2005-10-28 2007-05-17 Hosokawa Funtai Gijutsu Kenkyusho:Kk 核酸化合物封入ナノ粒子を含む経肺投与用医薬製剤
JP5078904B2 (ja) 2005-11-21 2012-11-21 ジヨンソン・アンド・ジヨンソン・リサーチ・ピーテイワイ・リミテツド 多標的干渉ｒｎａならびにそれらの使用および設計方法
EP1976986A2 (en) * 2005-12-30 2008-10-08 Intradigm Corporation Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment
US7846908B2 (en) * 2006-03-16 2010-12-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of TGF-beta and therapeutic uses thereof
CA2679387A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting akt gene expression and uses thereof
WO2008109548A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tgfb gene expression and uses thereof
JP2010519912A (ja) 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ｒａｓ遺伝子の発現を抑制するための核酸化合物およびその使用
CA2679244A1 (en) 2007-03-02 2009-03-05 Mdrna, Inc. Nucleic acid compounds for inhibiting myc gene expression and uses thereof
US20080287383A1 (en) 2007-03-02 2008-11-20 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
WO2008109362A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf gene expression and uses thereof
EP2126081A2 (en) 2007-03-02 2009-12-02 MDRNA, Inc. Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
CA2679339A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
CA2679757A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
US20100105134A1 (en) * 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
JP2010519907A (ja) 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ｖｅｇｆファミリー遺伝子の発現を抑制するための核酸化合物およびその使用
WO2008109357A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting apob gene expression and uses thereof
EP2126082A1 (en) 2007-03-02 2009-12-02 MDRNA, Inc. Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof
CN101674853B (zh) 2007-05-04 2013-03-27 玛瑞纳生物技术有限公司 氨基酸脂质及其用途
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
DK2217062T3 (en) * 2007-11-06 2015-08-24 Sirnaomics Inc MULTI-TARGET READY RNAi therapeutics TO ARFRI WOUND HEALING OF SKIN
UA97559C2 (uk) 2007-11-08 2012-02-27 Оцука Фармасьютікал Ко., Лтд. Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти
EP2238251B1 (en) * 2007-12-27 2015-02-11 Protiva Biotherapeutics Inc. Silencing of polo-like kinase expression using interfering rna
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
EP2264167B1 (en) 2008-03-31 2016-10-12 National Institute of Advanced Industrial Science and Technology Double-stranded lipid-modified rna having high rna interference effect
KR20180044433A (ko) 2010-03-24 2018-05-02 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
CN103200945B (zh) * 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
AR083445A1 (es) * 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS

Also Published As

Publication number Publication date
JP2020078314A (ja) 2020-05-28
EP2628798B1 (en) 2019-03-27
US9637743B2 (en) 2017-05-02
AU2011314653A1 (en) 2013-03-28
US20130217754A1 (en) 2013-08-22
SG189245A1 (en) 2013-05-31
TW201216988A (en) 2012-05-01
US20140288151A1 (en) 2014-09-25
US20190010500A1 (en) 2019-01-10
US8772262B2 (en) 2014-07-08
RU2013121802A (ru) 2014-11-20
JPWO2012050181A1 (ja) 2014-02-24
MX348555B (es) 2017-06-16
CA2813163C (en) 2020-11-03
HRP20190722T1 (hr) 2019-06-14
SG10201508365RA (en) 2015-11-27
US10125366B2 (en) 2018-11-13
EP2628798A4 (en) 2014-02-26
AU2011314653B2 (en) 2015-09-03
TWI572715B (zh) 2017-03-01
CN103119166A (zh) 2013-05-22
CN106086022B (zh) 2020-10-09
EP3517614A1 (en) 2019-07-31
US9273314B2 (en) 2016-03-01
IL224791A (en) 2017-09-28
PT2628798T (pt) 2019-05-14
CO6660456A2 (es) 2013-04-30
HUE043891T2 (hu) 2019-09-30
MX2013003698A (es) 2013-05-20
CN103119166B (zh) 2016-06-22
NZ630501A (en) 2015-11-27
IL245995A0 (en) 2016-07-31
LT2628798T (lt) 2019-05-10
PH12013500361A1 (en) 2022-03-30
WO2012050181A1 (ja) 2012-04-19
DK2628798T3 (da) 2019-05-06
US20160130586A1 (en) 2016-05-12
US20200291406A1 (en) 2020-09-17
CY1121945T1 (el) 2020-10-14
CN106086022A (zh) 2016-11-09
SG10201907649QA (en) 2019-09-27
ES2720135T3 (es) 2019-07-18
KR20180049152A (ko) 2018-05-10
TW201627012A (zh) 2016-08-01
JP2018088923A (ja) 2018-06-14
MY165964A (en) 2018-05-18
KR101853799B1 (ko) 2018-05-02
BR112013006541A2 (pt) 2017-09-19
JP6022940B2 (ja) 2016-11-09
KR20140020820A (ko) 2014-02-19
JP2017000155A (ja) 2017-01-05
US20170198293A1 (en) 2017-07-13
PL2628798T3 (pl) 2019-09-30
NZ609440A (en) 2014-10-31
EP2628798A1 (en) 2013-08-21
HK1184189A1 (zh) 2014-01-17
SI2628798T1 (sl) 2019-06-28
ZA201301279B (en) 2014-04-30
TR201905060T4 (tr) 2019-05-21
KR102167225B1 (ko) 2020-10-20
CA2813163A1 (en) 2012-04-19
IL245995B (en) 2018-05-31
TWI679023B (zh) 2019-12-11
RU2583290C2 (ru) 2016-05-10

Similar Documents

Publication Publication Date Title
PE20191351A1 (es) Tratamiento aav de la enfermedad de huntington
MX2025007610A (es) Composiciones de arni de 17beta-hidroxiesteroide deshidrogenasa tipo 13 (hsd17b13) y metodos de uso de las mismas
MX2021006745A (es) Constructos de iarn modificados quimicamente y usos de estos.
MX2017008500A (es) Supresión del gen de la huntingtina inducida por la arni.
AR090869A1 (es) COMPOSICIONES DE ARNi DE SERPINC1 Y SUS METODOS DE USO
MX2018012038A (es) Agentes de iarn modificados.
MX2024005652A (es) Agentes de acido ribonucleico (arn) de cadena doble modificados.
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
AR100946A1 (es) Composiciones y métodos para regular la expresión génica por medio de la interferencia de arn
WO2009017803A8 (en) Antisense microrna and uses therefor
AR083445A1 (es) siARN CONTRA LA FIBROSIS
PE20210921A1 (es) Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden
AR069821A1 (es) Composiciones y metodos de uso de la interferencia de arn para el control de nematodos
EP3456827A3 (en) Compositions and methods directed to treating liver fibrosis
EP4335502A3 (en) Modified u6 promoter system for tissue specific expression
AR084319A1 (es) INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
CO2018006947A2 (es) Novedoso bacteriófago pas-mup-1 de pasteurella multocida y su uso para inhibir la proliferación de pasteurella multocida
IN2014DN10899A (es)
CO2019010062A2 (es) Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens
WO2017007886A3 (en) Compositions for inhibiting dux4 gene expression and uses thereof
CL2021002842A1 (es) Moléculas inhibidoras de ácido nucleico bicatenario con cadenas de sentido acortadas
ES2671745T3 (es) Detección de Neisseria gonorrhoeae
AR102803A1 (es) Vacunas de reovirus aviar
CL2013003466A1 (es) Construcción de arn que comprende una secuencia de segmento sentido y una antisentido del gen p0 del genoma del virus del amarilleo moderado de la remolacha (bmyv), metodo para inducir tolerancia al virus bmyv.
UA117563C2 (uk) Композиція для лікування або профілактики хвороби, асоційованої з інфекцією впл

Legal Events

Date Code Title Description
FB Suspension of granting procedure